Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Myeloma | Pharmaceuticals